Co-authors Elisabetta Bugianesi and Frank Tacke join Louise Campbell and Roger Green to discuss the new MASLD Clinical Practice Guidelines from EASL, EASDand EASO.
Hannes Hagstrom joins the Surfers to discuss the value of VCTE or other in-office MASLD monitoring due to the results providing prognoses comparable or superior to biopsy and feedback for patient self-management.
Surfing NASH returns to its regular podcast schedule with a review of the recently concluded Paris NASH meeting. Presenters and KOLs Scott Friedman and Laurent Castera join Jörn Schattenberg, Louise Campbell and Roger Green for a fascinating session that focuses largely on important and emerging questions surrounding the use of NITs in a landscape which features drug approval. This opening conversation highlights the different presentations delivered by the guests followed by discussion around the liver as a regenerative organ and the use and limitations of NITs.
Ken Cusi and Roger Green are joined by family practice researcher and KOL Eric Johnson and diabetologist and primary care KOL Jay Shubrook in a discussion around exciting news emerging from the ADA 83rd Scientific Sessions meeting. Layering in practical takeaways, the group explores their impressions from the meeting, the utility of FIB-4 as a frontline screening tool, guidelines and recommendations, therapeutic options both now and in the imminent future, and lastly the new nomenclature rollout for Fatty Liver disease.
This final preview featuring the thoughts and anticipations of Louise Campbell and Roger Green explores the idea of harnessing technology to maximize the utility of databases in the effort of identifying patients.
This conversation covers final thoughts on the anticipations of Ian Rowe, Jörn Schattenberg and Roger Green heading into EASL Congress 2023. The group primarily explores a session on NAFLD clinical aspects which provides practical presentations around tools available now for treating and managing patients with NASH.
William Alazawi and Vanessa Hebditch join Louise Campbell and Roger Green to celebrate and comment on evidence-based guidance from NICE on FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care in the UK. This final conversation addresses a closing question around the future of FibroScan and how NICE will have progressed on the issue over the next 18 months.
William Alazawi and Vanessa Hebditch join Louise Campbell and Roger Green to celebrate and comment on evidence-based guidance from NICE on FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care in the UK. This conversation offers stimulating ideas around best ways to implement community screening.
William Alazawi and Vanessa Hebditch join Louise Campbell and Roger Green to celebrate and comment on evidence-based guidance from NICE on FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care in the UK. This conversation speculates on the value and accuracy of FAST and other tests. The group considers the importance of collecting data and what impact the guidance and experience in the UK will have for onlooking systems.
William Alazawi and Vanessa Hebditch join Louise Campbell and Roger Green to celebrate and comment on evidence-based guidance from NICE on FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care in the UK. This conversation focuses on the role of the British Liver Trust in this process and the importance of data collection for quality assurance.
